On-Body Isatuximab: Clinical Workflows and At-Home Potential in Myeloma

In the final installment of an Oncology Nursing News special three-part podcast series, Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, of Cleveland Clinic, and Sikander Ailawadhi, MD, of Mayo Clinic, analyzed the institutional integration, clinical workflows, and future care models for subcutaneous isatuximab-irfc (Sarclisa Escena). The discussion followed the U.S. Food and Drug Administration (FDA) approval of isatuximab-irfc administered via the CirCLIQ on-body delivery system (OBDS) across all approved multiple myeloma indications.